| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers.
|
J Natl Cancer Inst
|
1999
|
3.46
|
|
2
|
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
|
Blood
|
1993
|
2.98
|
|
3
|
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
|
N Engl J Med
|
1997
|
2.66
|
|
4
|
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.
|
Leukemia
|
2003
|
2.28
|
|
5
|
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.
|
N Engl J Med
|
1997
|
2.25
|
|
6
|
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains.
|
Kidney Int
|
2008
|
2.21
|
|
7
|
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.
|
Br J Haematol
|
2001
|
2.10
|
|
8
|
Thalidomide as initial therapy for early-stage myeloma.
|
Leukemia
|
2003
|
2.02
|
|
9
|
Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.
|
J Clin Oncol
|
2001
|
2.00
|
|
10
|
Testicular lymphoma is associated with a high incidence of extranodal recurrence.
|
Cancer
|
2000
|
1.95
|
|
11
|
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
|
Leukemia
|
2011
|
1.92
|
|
12
|
Primary renal non-Hodgkin's lymphoma. An unusual extranodal site.
|
Cancer
|
1995
|
1.82
|
|
13
|
True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases.
|
Blood
|
1995
|
1.81
|
|
14
|
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas.
|
Leukemia
|
2007
|
1.79
|
|
15
|
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
|
Leukemia
|
2007
|
1.66
|
|
16
|
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
|
Leukemia
|
2005
|
1.51
|
|
17
|
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.
|
Leukemia
|
2011
|
1.50
|
|
18
|
Complete resolution of reflex sympathetic dystrophy with thalidomide treatment.
|
Arch Intern Med
|
2001
|
1.47
|
|
19
|
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival.
|
J Clin Oncol
|
2001
|
1.45
|
|
20
|
Bowel perforation in intestinal lymphoma: incidence and clinical features.
|
Ann Oncol
|
2013
|
1.41
|
|
21
|
Osseous Hodgkin disease.
|
Cancer
|
1999
|
1.41
|
|
22
|
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
|
Leukemia
|
2001
|
1.36
|
|
23
|
Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
|
Leukemia
|
1996
|
1.33
|
|
24
|
Thalidomide in the treatment of relapsed multiple myeloma.
|
Mayo Clin Proc
|
2000
|
1.30
|
|
25
|
Prognostic value of bone marrow angiogenesis in multiple myeloma.
|
Clin Cancer Res
|
2000
|
1.28
|
|
26
|
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.
|
Leukemia
|
2012
|
1.27
|
|
27
|
Long-term survival (10 years or more) in 30 patients with primary amyloidosis.
|
Blood
|
1999
|
1.24
|
|
28
|
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
|
Eur J Nucl Med
|
2000
|
1.22
|
|
29
|
Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma.
|
Blood
|
1996
|
1.21
|
|
30
|
Expression of VEGF and its receptors by myeloma cells.
|
Leukemia
|
2003
|
1.18
|
|
31
|
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
|
Oncogene
|
2009
|
1.18
|
|
32
|
The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling.
|
Leukemia
|
2010
|
1.15
|
|
33
|
Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.
|
Leukemia
|
2011
|
1.15
|
|
34
|
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
|
Crit Rev Oncol Hematol
|
2001
|
1.14
|
|
35
|
Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer.
|
Cytometry
|
1993
|
1.11
|
|
36
|
Chronic natural killer cell lymphocytosis: a descriptive clinical study.
|
Blood
|
1994
|
1.09
|
|
37
|
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis.
|
Blood
|
2001
|
1.05
|
|
38
|
Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation.
|
Bone Marrow Transplant
|
1997
|
1.05
|
|
39
|
Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation.
|
Am J Hematol
|
2001
|
1.04
|
|
40
|
Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature.
|
Neurology
|
1991
|
1.03
|
|
41
|
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
|
Ann Oncol
|
2013
|
1.03
|
|
42
|
Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.
|
Bone Marrow Transplant
|
2004
|
1.02
|
|
43
|
CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations.
|
Leukemia
|
2005
|
1.01
|
|
44
|
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.
|
Bone Marrow Transplant
|
2003
|
1.01
|
|
45
|
Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells.
|
Leukemia
|
2002
|
1.01
|
|
46
|
Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies.
|
Mayo Clin Proc
|
1987
|
1.00
|
|
47
|
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
|
Cancer Treat Rev
|
2000
|
1.00
|
|
48
|
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy.
|
Bone Marrow Transplant
|
2004
|
0.99
|
|
49
|
Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis.
|
J Clin Oncol
|
1999
|
0.99
|
|
50
|
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
|
Clin Cancer Res
|
1999
|
0.99
|
|
51
|
A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth.
|
J Immunol
|
1997
|
0.98
|
|
52
|
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
|
Leukemia
|
2010
|
0.96
|
|
53
|
Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma.
|
Blood
|
1999
|
0.96
|
|
54
|
Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol.
|
Cancer
|
1994
|
0.95
|
|
55
|
Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
|
Bone Marrow Transplant
|
2000
|
0.95
|
|
56
|
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma.
|
Bone Marrow Transplant
|
2004
|
0.95
|
|
57
|
Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors.
|
Cancer
|
1993
|
0.95
|
|
58
|
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
|
Leukemia
|
2004
|
0.93
|
|
59
|
Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis.
|
Leuk Lymphoma
|
2002
|
0.93
|
|
60
|
A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.
|
Blood
|
2001
|
0.93
|
|
61
|
Elevated serum LDH in patients with non-Hodgkin's lymphoma: not always an ominous sign.
|
Br J Haematol
|
1999
|
0.93
|
|
62
|
Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.
|
Bone Marrow Transplant
|
1999
|
0.92
|
|
63
|
A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma.
|
Leukemia
|
1995
|
0.92
|
|
64
|
Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study.
|
J Clin Oncol
|
1995
|
0.90
|
|
65
|
Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.
|
J Clin Oncol
|
1997
|
0.90
|
|
66
|
Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
|
J Am Acad Dermatol
|
1996
|
0.89
|
|
67
|
Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia.
|
Am J Clin Pathol
|
1996
|
0.87
|
|
68
|
Giant uterine fibromyoma producing secondary polycythemia.
|
Obstet Gynecol
|
1994
|
0.87
|
|
69
|
Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil.
|
Br J Haematol
|
2000
|
0.86
|
|
70
|
Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1).
|
Am J Hematol
|
1985
|
0.86
|
|
71
|
Disseminated Kaposi's sarcoma after heart transplantation: association with Kaposi's sarcoma-associated herpesvirus.
|
J Heart Lung Transplant
|
1998
|
0.84
|
|
72
|
Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma.
|
Leukemia
|
1999
|
0.84
|
|
73
|
Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
|
J Clin Oncol
|
1999
|
0.84
|
|
74
|
A randomized, placebo-controlled study of outpatient premedication for bone marrow biopsy in adults with lymphoma.
|
Clin Lymphoma
|
2000
|
0.83
|
|
75
|
Autologous stem cell transplantation for relapsed and primary refractory myeloma.
|
Bone Marrow Transplant
|
1999
|
0.83
|
|
76
|
Carcinoid tumor of the rectum. DNA ploidy is not a prognostic factor.
|
Dis Colon Rectum
|
1996
|
0.83
|
|
77
|
Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis.
|
Med Oncol
|
1999
|
0.83
|
|
78
|
Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement.
|
Leuk Lymphoma
|
1999
|
0.82
|
|
79
|
Is persistent polyclonal B lymphocytosis caused by Epstein-Barr virus? A study with polymerase chain reaction and in situ hybridization.
|
Am J Hematol
|
1992
|
0.82
|
|
80
|
Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma.
|
Bone Marrow Transplant
|
2000
|
0.82
|
|
81
|
Spectrum of diseases associated with increased proportions or absolute numbers of peripheral blood natural killer cells.
|
Br J Haematol
|
1996
|
0.82
|
|
82
|
Diagnosis of B-cell non-Hodgkin's lymphoma of the central nervous system by immunocytochemical analysis of cerebrospinal fluid lymphocytes.
|
Cancer
|
1986
|
0.82
|
|
83
|
p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis.
|
J Natl Cancer Inst
|
1994
|
0.81
|
|
84
|
Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
|
Br J Haematol
|
1995
|
0.81
|
|
85
|
MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts.
|
Blood Cancer J
|
2011
|
0.81
|
|
86
|
Unusual presentation of extranodal peripheral T-cell lymphomas with multiple paraneoplastic features.
|
Cancer
|
1991
|
0.81
|
|
87
|
Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases.
|
Br J Haematol
|
1998
|
0.81
|
|
88
|
Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma.
|
Leuk Lymphoma
|
1999
|
0.80
|
|
89
|
Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma.
|
Blood
|
1989
|
0.80
|
|
90
|
Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
|
Arch Intern Med
|
1995
|
0.80
|
|
91
|
Thalidomide as an anti-cancer agent.
|
J Cell Mol Med
|
2002
|
0.80
|
|
92
|
Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma.
|
Blood Cancer J
|
2013
|
0.80
|
|
93
|
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma.
|
Leukemia
|
2011
|
0.79
|
|
94
|
Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis.
|
Am J Hematol
|
1999
|
0.79
|
|
95
|
Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma.
|
Am J Hematol
|
1989
|
0.79
|
|
96
|
Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.
|
N Engl J Med
|
2000
|
0.79
|
|
97
|
Splenectomy in advanced chronic lymphocytic leukemia: a single institution experience with 50 patients.
|
Am J Med
|
1992
|
0.78
|
|
98
|
Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.
|
J Clin Oncol
|
1994
|
0.78
|
|
99
|
Effect of sonication on paraffin-embedded tissue preparation for DNA flow cytometry.
|
Cytometry
|
1990
|
0.78
|
|
100
|
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).
|
Ann Oncol
|
2001
|
0.77
|
|
101
|
Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma.
|
Leukemia
|
2011
|
0.77
|
|
102
|
Effects of phenylacetate on cells from patients with B-chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
1994
|
0.77
|
|
103
|
T-cell chronic lymphocytic leukemia with a helper/inducer membrane phenotype: a distinct clinicopathologic subtype with a poor prognosis.
|
Am J Hematol
|
1986
|
0.77
|
|
104
|
Confirmation of lymphomatous pulmonary involvement by immunophenotypic and gene rearrangement analysis of bronchoalveolar lavage fluid.
|
Mayo Clin Proc
|
1990
|
0.76
|
|
105
|
Proliferative activity in non-Hodgkin's lymphomas. A comparison of the bromodeoxyuridine labeling index with PCNA immunostaining and quantitative image analysis.
|
Am J Clin Pathol
|
1993
|
0.76
|
|
106
|
Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2002
|
0.76
|
|
107
|
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
|
Bone Marrow Transplant
|
1999
|
0.76
|
|
108
|
Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
|
Leukemia
|
2007
|
0.75
|
|
109
|
Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
|
Bone Marrow Transplant
|
1997
|
0.75
|
|
110
|
A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia.
|
Leukemia
|
2001
|
0.75
|
|
111
|
Role of plasmapheresis in thrombocytopenic purpura associated with Waldenström's macroglobulinemia.
|
Mayo Clin Proc
|
1996
|
0.75
|
|
112
|
Oncogene expression in T-cell lymphoproliferative disorders.
|
Leuk Res
|
1988
|
0.75
|
|
113
|
Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis.
|
Br J Haematol
|
1998
|
0.75
|
|
114
|
Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia.
|
Am J Clin Oncol
|
1999
|
0.75
|
|
115
|
Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index.
|
Leuk Lymphoma
|
1999
|
0.75
|
|
116
|
Platelet transfusion therapy in acute leukemia: lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage.
|
Am J Hematol
|
1985
|
0.75
|
|
117
|
Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia.
|
Cancer Genet Cytogenet
|
1997
|
0.75
|
|
118
|
Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone.
|
Med Oncol
|
1999
|
0.75
|
|
119
|
Prognostic relevance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.
|
Cancer Genet Cytogenet
|
1999
|
0.75
|
|
120
|
Refractory and relapsing multiple myeloma treated by blood stem cell transplantation.
|
Am J Med Sci
|
1995
|
0.75
|
|
121
|
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling index.
|
Hematol Pathol
|
1991
|
0.75
|
|
122
|
Lymphoproliferative disorders of the head and neck.
|
Am J Otolaryngol
|
1991
|
0.75
|
|
123
|
Elevated liver enzymes preceding vessel involvement in Takayasu's arteritis.
|
J Hepatol
|
1999
|
0.75
|
|
124
|
Measurement of the cell proliferation rate of bone marrow erythroid precursors by flow cytometry: initial applications to multiple myeloma.
|
Leuk Lymphoma
|
1998
|
0.75
|
|
125
|
Bone marrow aspirate immunofluorescent and bone marrow biopsy immunoperoxidase staining of plasma cells in histologically occult plasma cell proliferative marrow disorders.
|
Arch Pathol Lab Med
|
1994
|
0.75
|